Enhancement of NK-cell activity in normal and tumor-bearing mice after administration of aclacinomycin.
Aclacinomycin (ACM) a new cytotoxic antibiotic employed in cancer chemotherapy, can either enhance or inhibit the NK-cell activity of the immune system, depending on the dose administered. A single intraperitoneal injection of 2-4 mg/kg of ACM augments the cytolytic activity by spleen and peritoneal exudate cells of normal mice and spleen cells depleted of nylon-adherent cells and peritoneal exudate cells of tumor-bearing mice. In contrast to the stimulatory effect of NK-cell activity by low doses of ACM, a single injection of 8 mg/kg of this agent leads to depression in the level of NK-cell activity in both normal and tumor-bearing animals. We suggest that the mechanism through which the ACM enhances NK-cell activity may be through the deletion of a suppressor cell population acting on the NK cells.
Andrade Mena
C E
CE
Orbach-Arbouys
S
S
Mathé
G
G
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000818:Animals; D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical; D007274:Injections, Intraperitoneal; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009279:Naphthacenes / Q000276:immunology / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology*; D010529:Peritoneal Cavity / Q000187:drug effects / Q000276:immunology; D013154:Spleen / Q000187:drug effects / Q000276:immunology
D009279:Naphthacenes; C011157:aclacinomycins; D015250:Aclarubicin